2- hydroxypropyl)-β-cyclodextrin ds~4.5; hpbcd  (Cyclolab R D Ltd)

Journal: Cell Death & Disease

Article Title: Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC

doi: 10.1038/s41419-022-05341-3

Figure Lengend Snippet: A Mice were implanted with HCC tumors and weighed starting the third day post-implantation. Tumor volume was measured in the groups once every three days. B ML-323 can enhance the therapeutic effect of sorafenib. HCCLM3 cells were grown into BALB/c-nu mice:(1)10%2-hydroxypropyl-β-cyclodextrin treated- mice, (2) ML-323-treated mice, (3) sorafenib-treated mice, and (4) ML-323+ sorafenib-treated mice. Tumor weights of the tumors in the four groups were recorded. C Tumor weights of the four groups. D Tumor volumes of four groups. E Immunohistochemical staining of tumor specimens. F HCCLM3 was inoculated into the orthotopic livers of nude mice and treated with ML-323 and 10%2-hydroxypropyl-β-cyclodextrin. G Hematoxylin and eosin (HE) staining of mouse lung tissue sections. H Lung metastasis of HCC in situ in mice treated with ML-323 or 10%2-hydroxypropyl-β-cyclodextrin was analyzed. Scale bars = 50 μm; * P < 0.05, ** P < 0.01, *** P < 0.001, significantly different compared to the control group.

Article Snippet: The tumor-bearing mice were randomly divided into four groups, each group included five mice ( n = 5) and treated with 10% 2-hydroxypropyl-β-cyclodextrin (HPBCD) (Sigma-Aldrich) or ML-323 (20 mg/kg) or sorafenib (30 mg/kg) or ML-323 sorafenib every 3 days.

Techniques: Immunohistochemical staining, Staining, In Situ